Orthopedic Applications of Platelet-Rich Plasma
Customize your policy alerts
Sign up for Capital Bluecross Policy MP 4.039 alerts
Get alerted when Policy MP 4.039 changes without checking for updates manually.
Monitor payer policy activity
Governs coverage of autologous platelet-rich plasma for orthopedic indications and adjunctive surgical use for Capital BlueCross members; states the payer's investigational stance and summarizes clinical rationale and related policy cross-references.
No material clinical or coverage changes in this revision.
Coverage Criteria — Orthopedic PRP
inv-01: Investigational (Not covered) — All orthopedic indications
Covered when ALL of the following are met
Includes primary injections for tendinopathies, plantar fasciitis, osteochondral lesions, osteoarthritis, and adjunctive use in listed surgeries; see exclusions for specific enumerated indications.
inv-02: Long bone nonunion — evidence summary and coverage stance
Long bone nonunion — evidence summary and coverage stance
One trial showed increased proportion healed in modified ITT but not in ITT; overall evidence insufficient.
inv-03: Rotator cuff repair — evidence summary and coverage stance
Rotator cuff repair — evidence summary and coverage stance
10-year follow-up and newer RCTs failed to show consistent superiority; variability in PRP preparation limits generalizability.
inv-04: Spinal fusion — evidence summary and coverage stance
Spinal fusion — evidence summary and coverage stance
Small trials and mixed observational data; no consistent benefit demonstrated.
inv-05: Other orthopedic procedures — Subacromial decompression and total knee arthroplasty evidence & stance
Subacromial decompression and total knee arthroplasty — evidence summary and coverage stance
Findings require confirmation in larger studies.
This policy applies to autologous platelet-rich plasma (PRP) used for orthopedic indications. Use of platelet-rich plasma is considered investigational for all orthopedic indications because there is insufficient evidence to support a general conclusion about health outcomes or benefits. Examples included in this investigational determination comprise primary injection use for Achilles tendinopathy, lateral epicondylitis, plantar fasciitis, osteochondral lesions, and osteoarthritis, as well as adjunctive use in surgeries such as anterior cruciate ligament reconstruction, hip fracture repair, long-bone nonunion, patellar tendon repair, rotator cuff repair, spinal fusion, subacromial decompression, and total knee arthroplasty.
Coding note: Procedure code 0232T is listed as investigational and therefore not covered when used for orthopedic applications. Providers should bill according to member benefit terms, but recognize that use of 0232T for orthopedic PRP procedures is identified as investigational in this policy.
The extracted sections of the policy do not present any additional, separate explicit coverage exclusion statements beyond the investigational stance and the coding note; policy history and related administrative notes are documented but no other explicit exclusions were listed in these chunks.
Restating the policy position: PRP is considered investigational for all orthopedic indications. As a result, PRP use for the orthopedic conditions enumerated in this policy is not considered a covered, medically necessary treatment under the terms reflected in these policy excerpts.
Orthopedic indications discussed in the policy include both primary injection indications and surgical adjuncts. Primary injection indications listed include Achilles tendinopathy, lateral epicondylitis, plantar fasciitis, osteochondral lesions, and osteoarthritis. Surgical adjunctive uses enumerated include anterior cruciate ligament reconstruction, hip fracture repair, long-bone nonunion, patellar tendon repair, rotator cuff repair, spinal fusion, subacromial decompression, and total knee arthroplasty. Evidence summaries for specific indications (for example, long-bone nonunion and rotator cuff repair) are discussed elsewhere in the policy and were judged insufficient to demonstrate improved net health outcomes.
The sections of the policy extracted for review do not use the phrase "not medically necessary" in listing specific conditions; instead, they describe PRP as "investigational for all orthopedic indications" and summarize the evidence base and rationale for that investigational determination, with references and guidance citations provided.
Coding — Procedure Codes and Billing
Provider Actions — Authorization, Documentation, and Billing
Verify program- and product-specific prior authorization rules
This policy applies only to certain Capital Blue Cross programs and products and coverage may vary by member benefit; verify the member’s specific plan rules and any product-specific prior authorization requirements before providing PRP for orthopedic indications.
- Confirm the member’s benefit program and eligibility on the date of service.
- Contact Provider Services or Member Services for questions about product-specific PA rules.
0232T is investigational (not covered) for orthopedic uses
Procedure code 0232T is listed in this policy as investigational and therefore not covered for orthopedic applications; providers should bill accordingly and recognize coverage depends on the member’s benefit terms.
- Do not assume coverage for CPT 0232T for orthopedic uses — the policy designates it investigational/not covered for orthopedic applications.
- Review member benefit contract for any exceptions before submitting a claim.
No specific PA requirements stated in these sections — verify plan rules
The extracted policy sections do not specify any universal prior authorization requirements for PRP; providers must refer to the member’s plan documents or other sections of Capital Blue Cross policies for actual PA rules.
- If a PA is required by the member’s benefit plan, include clinical rationale and supporting documentation per that plan’s PA process.
No step therapy specified in policy excerpts — check benefit plan
No step therapy requirements for PRP are specified in the provided policy chunks; follow the member’s benefit plan if it has any step therapy protocols.
- If the member’s plan includes step therapy, document prior conservative treatments as required by the plan prior to PRP consideration.
No step therapy requirements listed
These extracted sections do not list any step therapy requirements for PRP; providers should not assume a step therapy pathway from this policy alone and must verify with the member’s plan.
No step therapy actions required per these excerpts
No step therapy obligations are stated in the provided document chunks; for treatment sequencing requirements, consult the applicable benefit plan or other Capital Blue Cross policy references.
Document PRP product and preparation details
Document the specific PRP product or preparation system used (device name, manufacturer, and preparation method) because multiple FDA‑cleared devices and variable preparation techniques can affect platelet concentration and regulatory status.
- Record device/system name (eg, Aurix, SafeBlood, Magellan, GPS II) and whether the use was on- or off‑label.
- Include preparation details: centrifugation method, activation (thrombin/calcium), leukocyte content if known, and volume applied or injected.
Claims are subject to benefit terms, eligibility, and medical necessity
Claims and payment are subject to the member’s benefit program, eligibility on the date of service, and a determination that services are medically necessary and appropriate; contact Provider or Member Services for questions about coverage or claims processing.
- Include member eligibility and benefit verification in the patient record and any PA submission.
- Ensure documentation supports medical necessity per the member’s contract.
Keep policy history and revision notes with the record or PA documentation
Maintain the policy history and revision notes relevant to MP 4.039 in the medical record or in prior authorization documentation when applicable, particularly when citing policy rationale for coverage decisions.
- Reference the policy number (MP 4.039) and the effective/review dates when documenting coverage rationale.
- Retain copies or notation of policy updates that influenced the prior authorization or denial decision.
Investigational designation — risk of claim denial for orthopedic PRP
Use of PRP for orthopedic indications is designated investigational in this policy; claims submitted for these indications are therefore subject to denial as investigational treatment.
- If submitting a claim for PRP in orthopedic indications listed in the policy, include robust clinical justification and evidence if seeking coverage consideration under exceptional circumstances.
- Be prepared for potential denial and follow the member’s appeal processes if applicable.
Coding-based denial risk for CPT 0232T
Billing or submitting CPT code 0232T for orthopedic applications may trigger a denial because the code is listed as investigational and not covered for these uses in this policy.
- Avoid separate billing of 0232T for orthopedic indications unless the member’s specific benefit contract allows it.
- If billed, include documentation of the clinical indication and benefit plan exception requests as appropriate.
No additional explicit denial triggers listed in these excerpts
The provided document chunks do not list explicit procedural denial triggers beyond the investigational stance and coded exclusions; follow the policy language and member benefit terms when preparing documentation to mitigate denials.
- Ensure clinical records reflect the investigational status if electing to proceed and document any benefit exceptions or prior authorization determinations.
Background — PRP Overview and Rationale
Background: Platelet-rich plasma (PRP) is an autologous concentrate of a patient’s own platelets suspended in plasma that, when activated, releases growth factors (for example, platelet-derived growth factor and transforming growth factor) intended to stimulate cellular processes involved in healing. PRP can be applied as a gel during surgery or injected into tissues; preparation methods and devices vary, producing variable platelet concentrations and products.
Definitions
Policy Revision History
Editorial refinements to the policy statement, updated product variation statement and references; removed HCPCS code P9020 as it will be vendor managed.
Updated rationale and references; no changes to coding.
Updated cross-references, FEP, rationale, and references; removed code 86999.
Updated cross references, background, and references; added HCPCS code P9020.
FEP and references updated; coding reviewed.
References and rationale updated; coding reviewed.
Consensus review with rationale and references updated; no change to policy statement.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.